Meanwhile, antidepressant drugs may exert beneficial effects on the insulin receptor phosphorylation pathway through the Shc1/Grb2 complex (50), which further supports the potential use of Sch1 for depression drug development. Here, SHC1 is linked to depressive symptom measurement.